Novel Monoclonal Antibody Shows Promise in Ulcerative Colitis

(MedPage Today) -- Significantly more patients with moderately to severely active ulcerative colitis achieved clinical remission with the investigational monoclonal antibody tulisokibart compared with placebo, a randomized phase II trial showed...